Track topics on Twitter Track topics that are important to you
Despite improvements in perioperative care, non-cardiac surgery remains associated with significant and costly complications. Analysis of perioperative deaths in the United Kingdom suggests that roughly 80% are directly attributable to infectious and cardiovascular complications. The best available evidence suggests that medical optimization is the preferred strategy to reduce cardiac risks but there has been no novel strategy to reduce nosocomial infection rates in over 20 years.
Emerging evidence in both the non-operative and operative setting suggest that statin drugs may prevent both infectious and cardiac events. The mechanism(s) of action are not entirely clear but appear to independent of lipid lowering effects and are often referred to as pleiotropic effects. Two key elements of the pleiotropic effects of statins appear to be their anti-inflammatory properties and improved endothelial vascular reactivity. The statin dose required to maximize these effects is unknown. A large observational trial suggests a contradictory dose effect with higher doses associated with reduced infectious complications and lower doses associated with fewer cardiac complications. Doctors therefore still have many unanswered questions about the use of statins in the perioperative setting. Should they be routinely started on all or only certain surgical patients? What dose of statin should be used? If a patient is already on a statin, should their dose be altered perioperatively? The latter question is particularly relevant in light of the marked increase in statin use. Recruitment logs for an ongoing trial demonstrate that over 70% of patients undergoing high-risk surgery were taking a statin but at markedly variable doses. This population presents an ideal opportunity to determine if there is a dose response relationship between statins and pleiotropic effects. We therefore propose an observational study that will determine anti-inflammatory and endothelial effects in high-risk surgical patients on varying doses of a perioperative statin drug.
Atorvastatin diminishes the rise in C-reactive protein (CRP), measured 48 hours after elective vascular surgery, in a dose dependent fashion.
Atorvastatin reduces endothelial dysfunction after elective vascular surgery, as measured by brachial artery ultrasound, in a dose dependent fashion.
It is estimated that approximately 1.7 million surgical procedures are performed each year in Canada. Unfortunately, perioperative complications are not an uncommon occurrence and have substantial morbidity, mortality and costs associated with them. To date, the best strategies to reduce nosocomial infections are aseptic practices, timely prophylactic antibiotics and good surgical technique. Despite these strategies, it is estimated that at least 1 in 5 major vascular surgical patients will have some type of nosocomial infection within 30 days of their procedure. The direct and indirect mortality of infections in this population is difficult to estimate but nosocomial infections are estimated to contribute to at least 15% of the mortality in hospitalized patients.
The primary manner in which infections contribute to patient mortality is by progression to sepsis. Sepsis is the tenth leading cause of death in Canadians and worldwide is increasing in incidence and severity. The associated mortality of sepsis varies by population and infection source but is usually between 30-60%. Despite significant improvements in the management of sepsis in the last 5 years, there is still no generally effective preventive medication or strategy. Although cardiovascular complications, including myocardial infarction and heart failure, are less common at 15% of major vascular patients, they have a staggering mortality of around 30-50%. Clearly, strategies or therapies to reduce these complications could have profound benefits. The questions are therefore whether statin drugs reduce sepsis, cardiovascular complications, or both and, if they do, how might they do so.
Understanding of the pathophysiology of sepsis and acute coronary syndromes in the non-operative setting has led to tremendous advancements in the management. In sepsis, an excessive, inappropriate and misguided response in the host defense response is likely responsible. Massive cytokine release exacerbates endothelium dysfunction that then impacts coagulation, thrombolysis, inflammation, tissue repair and tissue growth. If not corrected, the endothelial cells either die directly or through the triggering of apoptosis. This then leads to multiorgan dysfunction and ultimately death. How sepsis ultimately impairs and damages endothelial cell function is likely multifactoral. Impairment of endothelial nitric oxide synthetase occurs that causes impaired perfusion and inappropriate microvasculature coagulation.
In a strikingly similar manner to sepsis, key elements to acute coronary syndromes again appear to be inflammation and endothelial dysfunction. Rupture of coronary plaques and thrombosis are central. Although perioperative myocardial events are traditionally said to be supply-demand problems, this theory is in dispute and evidence suggests that perioperative problems are very similar to non-operative events. Elevated levels of various inflammatory markers, particularly C-Reactive Protein, are associated with adverse cardiovascular events. Similarly, the vascular endothelium is responsible for regulating vasomotor tone, thrombosis, platelet and leukocyte interactions. Dysfunction of the endothelium is also believed to be a central component of the development of coronary complications. Although endothelial dysfunction has not been extensively investigated in the perioperative setting, pathophysiologic similarities make it probable that perioperative endothelial dysfunction contributes to the occurrence of perioperative myocardial events. Thus, strategies designed to control perioperative inflammation, as well as to improve endothelial function and stabilize coronary plaque have the potential to reduce both perioperative coronary and infectious events.
Although studies in both animals and humans strongly suggest that statins may both prevent and treat sepsis, no prospective randomized trials in humans have been conducted to demonstrate these effects. Although some statins have been demonstrated to directly attenuate replication and infectivity of microorganisms, the evidence primarily suggests that if statins are indeed protective it will likely be due to their anti-inflammatory and favorable endothelial effects. Improvement of endothelial function by statins has been suggested to prevent cardiac events by stabilizing coronary plaques and may even contribute to plaque regression. Statins restore endothelial production of endogenous nitric oxide synthetase thus improving organ perfusion and microvasculature thrombosis that is impaired in the setting of sepsis.
The goals of the proposed trial, STAR VaS II are therefore twofold: First, it will help determine if statin blunts the adverse perioperative changes in inflammation and endothelial function in a dose-dependent fashion. Second, it will determine if patients chronically on lower than maximal statin dose should have their dose increased in the perioperative period. We will evaluate the influence of varying doses of statins on perioperative inflammation, as assessed by C-reactive protein, and endothelial function as assessed by brachial artery ultrasound. If atorvastatin, chronically administered before surgery, improves inflammatory changes or endothelial function in a dose dependent fashion, then it is plausible that patients chronically on lower statin doses should have their dose increased in the perioperative period. If however patients on lower doses experienced similar benefit, as those on higher doses, then conceivably the recommended perioperative dose could be lower thereby theoretically further improving the risk-benefit ratio for a statin drug. All patients will be assessed for infections as defined by the CDC.
Observational Model: Case-Only, Time Perspective: Prospective
Atorvastatin, Atorvastatin, Atorvastatin, Atorvastatin, Control
The Ottawa Hospital
Ottawa Hospital Research Institute
Published on BioPortfolio: 2014-07-23T21:13:31-0400
To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
The primary objective of the study is to investigate the ratios of p-hydroxyatorvastatin to atorvastatin in patients receiving atorvastatin treatment, who experience muscle adverse events,...
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to ...
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
This article explores the effects of atorvastatin on cultured breast cancer cells. Our experiment demonstrated that atorvastatin triggered autophagy and inhibited proliferation in breast cancer cells....
The interaction of atorvastatin with calf thymus DNA (CT-DNA) was investigated in vitro under simulated physiological conditions by using absorption and emission spectroscopy, viscosity measurements, ...
We tested whether intervention with atorvastatin affects the prostate beneficially compared with placebo in men with prostate cancer in a randomized clinical trial. A total of 160 statin-naïve prosta...
In the present study, we investigated the hypolipidemic and hepatoprotective potential of the commercially available crushed Ajwa date seed-extract on the toxicity caused by the atorvastatin in high-f...
Atorvastatin is a lipid-regulating drug that is commonly used in clinical practice and can stabilize plaques. Increasing evidence shows that statins have anti-heart failure effects, but their specific...
A pyrrole and heptanoic acid derivative,HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; AND TRIGLYCERIDES and to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS and prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.
Inflammation of the PERIAPICAL TISSUE. It includes general, unspecified, or acute nonsuppurative inflammation. Chronic nonsuppurative inflammation is PERIAPICAL GRANULOMA. Suppurative inflammation is PERIAPICAL ABSCESS.
The use of biological mechanisms, usually involving living organisms such as bacteria, for the reduction or regulation of the population of noxious, destructive, or dangerous pests. Environmental concerns have focused attention on natural forms of disease control as potentially safe and effective alternatives to chemical pesticides. This has led to increased efforts to develop control strategies that rely on natural predators and parasites or that involve genetically engineered microbial pest control agents.
Inflammation of the lung parenchyma that is associated with PLEURISY, inflammation of the PLEURA.
Those forms of control which are exerted in less concrete and tangible ways, as through folkways, mores, conventions, and public sentiment.
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...